{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:12:23Z","timestamp":1788840743875,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.coph.2026.102649","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:18:02Z","timestamp":1783495082000},"page":"102649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical pharmacokinetics of afatinib: A systematic review"],"prefix":"10.1016","volume":"90","author":[{"given":"Tehreem","family":"Ikram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammara","family":"Zamir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Majeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faleh","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8607-8583","authenticated-orcid":false,"given":"Muhammad Fawad","family":"Rasool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2026.102649_bib1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/jpet.112.197756","article-title":"Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker","volume":"343","author":"Solca","year":"2012","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.coph.2026.102649_bib2","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1093\/annonc\/mdw322","article-title":"Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-lung 3 and 6 trials","volume":"27","author":"Yang","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.coph.2026.102649_bib3","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc. GilotrifTM (afatinib) tablets, for oral use: US prescribing information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/201292s014lbl.pdf accessed on 18 May 2025. ."},{"key":"10.1016\/j.coph.2026.102649_bib4","unstructured":"European medicine agency (Giotrif)https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/giotrif acessed on 24 apil 2025."},{"key":"10.1016\/j.coph.2026.102649_bib5","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s10549-012-2126-1","article-title":"A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer","volume":"134","author":"Schuler","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 1","key":"10.1016\/j.coph.2026.102649_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0025-7753(16)30257-3","article-title":"[Mechanism of action and preclinical development of afatinib]","volume":"146","author":"Diz Ta\u00edn","year":"2016","journal-title":"Med Clin"},{"key":"10.1016\/j.coph.2026.102649_bib7","doi-asserted-by":"crossref","first-page":"103506","DOI":"10.1016\/j.jddst.2022.103506","article-title":"Afatinib liposomal dry powder inhaler: targeted pulmonary delivery of EGFR inhibitor for the management of lung cancer","volume":"74","author":"Vanza","year":"2022","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.coph.2026.102649_bib8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40262-016-0440-1","article-title":"Clinical pharmacokinetics and pharmacodynamics of afatinib","volume":"56","author":"Wind","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.coph.2026.102649_bib9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10637-012-9904-9","article-title":"A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors","volume":"31","author":"Gordon","year":"2013","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.coph.2026.102649_bib10","article-title":"Guidance for industry.Drug interaction studies: study design, data analysis, implications for dosing, and labeling recommendations","year":"2012","journal-title":"US FDA guidance"},{"key":"10.1016\/j.coph.2026.102649_bib11","unstructured":"Drug Bank; Afatinib, drug bank ID# DB08916; https:\/\/go.drugbank.com\/drugs\/DB08916, accessed on 20 April 2025."},{"key":"10.1016\/j.coph.2026.102649_bib12","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s00280-011-1803-9","article-title":"Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers","volume":"69","author":"Stopfer","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.coph.2026.102649_bib13","unstructured":"National Center for Biotechnology Information.PubChem compound summary for Afatinib, CID[10184653]. Retrieved from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Afatinib accessed on 17 April 2025."},{"key":"10.1016\/j.coph.2026.102649_bib14","unstructured":"Raedler LA; Gilotrif (Afatinib): second-generation tyrosine kinase inhibitor indicated for the first-line treatment of patients with Non\u2013small-cell lung cancer and EGFR mutation."},{"key":"10.1016\/j.coph.2026.102649_bib15","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coph.2026.102649_bib16","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1188\/18.CJON.542-548","article-title":"Practical management of adverse events associated with afatinib","volume":"22","author":"Edwards","year":"2018","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.coph.2026.102649_bib17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40261-013-0161-2","article-title":"Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir","volume":"34","author":"Wind","year":"2014","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.coph.2026.102649_bib18","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s40265-013-0111-6","article-title":"Afatinib: first global approval","volume":"73","author":"Dungo","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.coph.2026.102649_bib19","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1517\/13543784.2014.924505","article-title":"Afatinib in the treatment of breast cancer","volume":"23","author":"Hurvitz","year":"2014","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.coph.2026.102649_bib20","first-page":"183","article-title":"Clinical and comparative utility of afatinib in non-small cell lung cancer","volume":"8","author":"D'Arcangelo","year":"2014","journal-title":"Biologics"},{"key":"10.1016\/j.coph.2026.102649_bib21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40265-013-0170-8","article-title":"Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer","volume":"74","author":"Keating","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.coph.2026.102649_bib22","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.2146\/ajhp130654","article-title":"Afatinib: a first-line treatment for selected patients with metastatic non-small-cell lung cancer","volume":"71","author":"Engle","year":"2014","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.coph.2026.102649_bib23","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2008"},{"key":"10.1016\/j.coph.2026.102649_bib24","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg"},{"key":"10.1016\/j.coph.2026.102649_sref44","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/cpdd.1134","article-title":"Pharmacokinetic and safety comparison of 2 afatinib dimaleate tablets in healthy Chinese volunteers under fasted conditions: a randomized, open-label, 2-Period, single-dose crossover study","volume":"11","author":"Shi","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.coph.2026.102649_bib34","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00280-014-2484-y","article-title":"Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment","volume":"74","author":"Schnell","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.coph.2026.102649_bib42","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/chromsci\/bmab040","article-title":"A sensitive LC-MS\/MS method for the determination of afatinib in human plasma and its application to a bioequivalence Study","volume":"60","author":"Luo","year":"2022","journal-title":"J Chromatogr Sci"},{"key":"10.1016\/j.coph.2026.102649_bib26","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00280-011-1738-1","article-title":"Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy\/erlotinib\/gefitinib (LUX-lung 4)","volume":"69","author":"Murakami","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.coph.2026.102649_sref43","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3390\/biology10101054","article-title":"Relationship between plasma concentrations of afatinib and the onset of diarrhea in patients with non-","volume":"10","author":"Yokota","year":"2021","journal-title":"Biology"},{"key":"10.1016\/j.coph.2026.102649_bib29","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00280-013-2286-7","article-title":"Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors","volume":"72","author":"Molife","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.coph.2026.102649_bib25","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.2009.26.7278","article-title":"Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors","volume":"28","author":"Yap","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2026.102649_bib28","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s40262-013-0091-4","article-title":"Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours","volume":"52","author":"Wind","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.coph.2026.102649_sref39","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s13318-016-0359-9","article-title":"Influence of renal impairment on the pharmacokinetics of afatinib: an open-label, single-dose study","volume":"42","author":"Wiebe","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.coph.2026.102649_sref46","doi-asserted-by":"crossref","first-page":"113695","DOI":"10.1016\/j.biopha.2022.113695","article-title":"Influence of esomeprazole on the bioavailability of afatinib: a pharmacokinetic cross-over study in patients with non-small cell lung cancer","volume":"155","author":"Veerman","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.coph.2026.102649_bib31","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s10637-012-9880-0","article-title":"Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors","volume":"31","author":"Awada","year":"2013","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.coph.2026.102649_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40064-015-1601-7","article-title":"A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole","volume":"5","author":"Gunzer","year":"2016","journal-title":"SpringerPlus"},{"key":"10.1016\/j.coph.2026.102649_bib33","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1007\/s10637-014-0139-9","article-title":"A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors","volume":"32","author":"Chu","year":"2014","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.coph.2026.102649_bib36","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2217\/fon.15.50","article-title":"A phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors","volume":"11","author":"Gordon","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.coph.2026.102649_bib47","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00280-014-2403-2","article-title":"Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors","volume":"73","author":"Freiwald","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.coph.2026.102649_bib48","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/clpt.2010.231","article-title":"Probabilistic risk analysis: improving early drug development decision making","volume":"88","author":"Mudd","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"suppl","key":"10.1016\/j.coph.2026.102649_bib49","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1200\/jco.2006.24.18_suppl.2074","article-title":"A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR\/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours","volume":"24","author":"Agus","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2026.102649_bib50","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40265-017-0729-x","article-title":"Clinical implications of P-glycoprotein modulation in drug\u2013drug interactions","volume":"77","author":"Lund","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.coph.2026.102649_bib51","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S1470-2045(13)70579-5","article-title":"Drug\u2013drug interactions with tyrosine-kinase inhibitors: a clinical perspective","volume":"15","author":"van Leeuwen","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coph.2026.102649_bib52","series-title":"Seminars in oncology","article-title":"Pemetrexed in gastric cancer: clinical experience and future perspectives","author":"Celio","year":"2002"},{"key":"10.1016\/j.coph.2026.102649_sref53","doi-asserted-by":"crossref","first-page":"104554","DOI":"10.1016\/j.jddst.2023.104554","article-title":"DOE supported optimization of biodegradable polymeric nanoparticles based dry powder inhaler for targeted delivery of afatinib in non-small cell lung cancer","volume":"84","author":"Vanza","year":"2023","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.coph.2026.102649_sref54","doi-asserted-by":"crossref","first-page":"105573","DOI":"10.1016\/j.jddst.2024.105573","article-title":"Assessment of nanocarrier mediated afatinib pharmacokinetic: a comparative in-vivo study in rat model for enhanced therapeutic efficacy in lung cancer management","volume":"95","author":"Vanza","year":"2024","journal-title":"J Drug Deliv Sci Technol"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489226000457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489226000457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:03:49Z","timestamp":1788840229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489226000457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":46,"alternative-id":["S1471489226000457"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2026.102649","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical pharmacokinetics of afatinib: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2026.102649","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102649"}}